Needham downgrades Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) from Buy to Hold, after ACP-104 trial fails in schizophrenia.

The firm ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE